Autolus Therapeutics plc ADR (NASDAQ: AUTL) on Monday, plunged -6.63% from the previous trading day, before settling in for the closing price of $1.66. Within the past 52 weeks, AUTL’s price has moved between $1.56 and $6.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 251.43% over the past five years. The company achieved an average annual earnings per share of -4.85%. With a float of $240.32 million, this company’s outstanding shares have now reached $266.13 million.
Let’s look at the performance matrix of the company that is accounted for 647 employees. In terms of profitability, gross margin is 61.23%, operating margin of -1635.99%, and the pretax margin is -2165.37%.
Autolus Therapeutics plc ADR (AUTL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Autolus Therapeutics plc ADR is 9.70%, while institutional ownership is 53.77%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.49% during the next five years compared to 21.36% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Autolus Therapeutics plc ADR (AUTL) is currently performing well based on its current performance indicators. A quick ratio of 10.77 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Autolus Therapeutics plc ADR (NASDAQ: AUTL) saw its 5-day average volume 1.05 million, a negative change from its year-to-date volume of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 15.94%. Additionally, its Average True Range was 0.13.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 1.15%, which indicates a significant decrease from 6.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.14% in the past 14 days, which was higher than the 69.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9507, while its 200-day Moving Average is $3.2000. Nevertheless, the first resistance level for the watch stands at $1.6133 in the near term. At $1.6767, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7233. If the price goes on to break the first support level at $1.5033, it is likely to go to the next support level at $1.4567. Assuming the price breaks the second support level, the third support level stands at $1.3933.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
Market capitalization of the company is 412.49 million based on 266,094K outstanding shares. Right now, sales total 10,120 K and income totals -220,660 K. The company made 30 K in profit during its latest quarter, and -27,610 K in sales during its previous quarter.
